Intracellular delivery is integral to the generation of engineered ex vivo cell-based therapies including genome editing approaches. Current delivery modalities, both viral and non-viral, have limitations which led Avectas to develop a technology that enables delivery of cargoes to cells for developing next-generation therapies. The SOLUPORE® technology is a patented non-viral, cell engineering technology that permeabilises the target cell membrane and allows efficient transfer of cargo into cells whilst retaining very high levels of cell viability and functionality.
The SOLUPORE® technology is versatile and enables delivery of nucleic acids such as mRNA, DNA and proteins, including gene editing tools such as CRISPR. The SOLUPORE® cell engineering platform achieves excellent engineering efficiencies in a variety of cell types including primary T cells and NK cells for immuno-oncology and gene editing applications.
WHAT MAKES THE SOLUPORE® TECHNOLOGY DIFFERENT
Avectas has developed a Research and Development device that is now available for technology transfer. This device replicates the clinical and commercial scale technology in a form which is easy to use for non-GMP R&D. A clinical device will be ready for the manufacture of cell therapies for clinical evaluation Q1 2022, including the regulatory documentation to support IND and ultimate BLA, or equivalent, regulatory filings. Avectas is additionally developing a continuous throughput system to enable larger volumes of cells to be engineered.
The SOLUPORE® platform has wide applicability for the engineering of next-generation gene modified cell therapy products, including those which will require multiple modifications using diverse gene editing tools, whilst preserving cell functionality.
Avectas will support its partners in the compilation of documentation for regulatory filings with CMC documentation and / or reference to Avectas DMFs.
Speak to us today about your need for multiple cell engineering strategies to create the most effective cell therapy.
Become a Partner
Avectas’ SOLUPORE® platform offers a cell engineering solution for next generation cell and gene therapies. Partnerships are essential to ensure better patient outcomes, and we are actively seeking to engage with companies and researchers who are developing these lifesaving gene modified cell therapy products.
If you would like to learn more about working with Avectas and our cell engineering technology, get in touch with us.